-
Company Insights
Innovation and Patenting activity of ABC-MART Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of ABC-MART Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABC-008 in T-Cell Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABC-008 in T-Cell Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ABC-008 in T-Cell LeukemiaDrug Details:AB-008 is under development for the treatment of inclusion...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABC-008 in Inclusion Body Myositis (IBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABC-008 in Inclusion Body Myositis (IBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABC-008 in Inclusion Body Myositis (IBM) Drug Details: AB-008 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KT-474 in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KT-474 in Hidradenitis Suppurativa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KT-474 in Hidradenitis Suppurativa Drug Details: KT-474 (KYM-001) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KT-474 in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KT-474 in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KT-474 in Atopic Dermatitis (Atopic Eczema) Drug Details: KT-474 (KYM-001)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CTX-177 in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTX-177 in Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CTX-177 in Non-Hodgkin Lymphoma Drug Details: CTX-177 (ONO-7018) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CTX-177 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTX-177 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CTX-177 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CTX-177 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTX-177 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CTX-177 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Company Insights
Business of the National Basketball Association (NBA) 2023-24 – Property Profile, Sponsorship and Media Landscape
Explore the following trends and insights from the ‘Business of the National Basketball Association (NBA)’ report: A comprehensive overview and expert insight into the NBA league, which is well regarded as the pinnacle of basketball globally. The sponsorship and media revenue generated for the 2023-2024 season. Break-down of the main commercial deals around each of the 30 competing teams from both a sponsorship and media perspective. Analyze the brands associated with the NBA to gain a competitive advantage. How is the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TGI-2 in Metastatic Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TGI-2 in Metastatic Melanoma Drug Details: TGI-2 (NM1F) is under development for the treatment of...